A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Hepatocellular Carcinoma Non-Resectable
Interventions
DEVICE

Magnesium Microspheres

Biodegradable Magnesium Embolic Microspheres

PROCEDURE

cTACE

cTACE

Trial Locations (10)

Unknown

The First Affiliated Hospital of Bengbu Medical University, Bengbu

Anyang Tumor Hospital, Anyang

Henan Cancer Hospital, Zhengzhou

Zhongda Hospital Southeast University, Nanjing

Lishui Central Hospital, Lishui

The Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou

The First Hospital of Lanzhou University, Lanzhou

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

Fudan University Shanghai Cancer Center, Shanghai

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
collaborator

CHONGQING BAIMAITENGSHI PHARMACEUTICAL TECHNOLOGY CO., LTD

UNKNOWN

lead

InnoBM Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06779461 - A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter